In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CardioMEMS, Inc.

http://www.cardiomems.com

Latest From CardioMEMS, Inc.

Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa

The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.

Clinical Trials Companies

Novel Anti-Hypertensive Treatment & NSCLC Drug Among New EU Filings

The European Medicines Agency has added five new drugs to its latest monthly list of medicines that are under review for potential EU marketing approval.

Europe Drug Review

Protagonist/J&J Explore Autoimmune FRONTIER With Positive Psoriasis Results

While full data are not yet available, JNJ-2113 would be the first oral drug against IL-23R, setting up for potential competition against oral TYK2 and IL-17-targeting drugs.

Clinical Trials Inflammation

Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension

Ampreloxetine failed in a Phase III trial in 2021, but the company will start a registrational trial by the end of Q1 for the drug in the multiple system atrophy population, where it has shown efficacy.

Sales & Earnings Cardiovascular
See All

Company Information

UsernamePublicRestriction

Register